Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation Clinical Trial
Official title:
A Multicentre Phase II Study of Adavosertib Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
| Verified date | August 2023 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.
| Status | Completed |
| Enrollment | 95 |
| Est. completion date | March 8, 2023 |
| Est. primary completion date | December 13, 2018 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years to 130 Years |
| Eligibility | Inclusion - Has read and understands the informed consent form (ICF) and has given written IC prior to any study specific procedures. - Histologic or cytologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer. - Progressed within 6 months of completing at least 4 cycles of a first-line platinum-containing regimen for Stage III/IV disease. Patients with refractory disease (progression during platinum-containing therapy) are ineligible. - No more than 2-4 prior treatment regimens for Stage III/IV disease, defined as investigational, chemotherapy, hormonal, biologic, or targeted therapy. - Prior doxorubicin (or other anthracycline) at a cumulative dose of = 360 mg/m² or cumulative epirubicin dose of = 720 mg/m² (calculated using doxorubicin equivalent doses: 1 mg of doxorubicin = 1 mg PLD = 0.3 mg mitoxantrone = 0.25 mg idarubicin). Subjects without any prior anthracycline exposure can also be included. Applies to Arm D only. - At least 1 measurable lesion according to RECIST v1.1. - Any prior palliative radiation therapy must be completed at least 7 days prior to start of study treatment and patients must have recovered from any acute adverse effects prior to start of study treatment. - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 - 1. - Baseline Laboratory Values: 1. ANC =1500/µL 2. HgB = 9 g/dL with no blood transfusions in the past 28 days 3. Platelets = 100,000/µL 4. ALT & AST =3 x ULN or =5 x ULN if known hepatic metastases 5. Serum bilirubin within normal limits (WNL) or =1.5 x the ULN in patients with liver metastases; or total bilirubin =3.0 x ULN with direct bilirubin WNL in patients with well documented Gilbert's Syndrome. 6. Serum creatinine =1.5 x the ULN and a calculated creatinine clearance (CrCl) =45 mL/min by the Cockcroft-Gault method. - Left ventricular ejection fraction (LVEF) WNL of the institution as determined by multiple uptake gated acquisition (MUGA) or echocardiography (ECHO) (applies to Arm D only). - Female patients, =18, (not of childbearing potential and fertile female patients of childbearing potential) who agree to use adequate contraceptive measures from 2 weeks prior to the study and until 1 month after study treatment discontinuation, who are not breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours prior to start. - Predicted life expectancy = 12 weeks Exclusion - Use of a study drug (approved or investigational drug therapy) =21 days or 5 half-lives (whichever is shorter) prior to the first dose of study treatment. For study drugs for which 5 half-lives is =21 days, a minimum of 10 days between termination of the study drug and administration of study treatment is required. - Major surgical procedures = 28 days of beginning study, or minor surgical procedures = 7 days. No waiting period following port-a-cath placement, or any other central venous access placement. - Grade >1 toxicity from prior therapy (except alopecia or anorexia). - Known malignant CNS disease other than neurologically stable, treated brain metastases, defined as metastasis having no evidence of progression or haemorrhage after treatment for at least 2 weeks (including brain radiotherapy). Must be off any systemic corticosteroids for the treatment of brain metastases for at least 14 days prior to enrolment. - Patient has had prescription or non-prescription drugs or other products (i.e. grapefruit juice) known to be sensitive CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong inhibitors or inducers of CYP3A4 which cannot be discontinued 2 weeks prior to Day 1 of dosing and withheld throughout the study until 2 weeks after last dose of study drug. - Caution should be exercised when inhibitors or substrates of P-gP, substrates of CYP1A2 with a narrow therapeutic range, sensitive substrates of CYP2C19 or CYP2C19 substrates with a narrow therapeutic range are administered with adavosertib. - Herbal medications should be discontinued 7 days prior to the first dose of study treatment. - Any of the following cardiac diseases currently or within the last 6 months as defined by New York Heart Association (NYHA) = Class 2: 1. Unstable angina pectoris 2. Congestive heart failure 3. Acute myocardial infarction 4. Conduction abnormality not controlled with pacemaker or medication 5. Significant ventricular or supraventricular arrhythmias (patients with chronic rate controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible). - Adavosertib should not be given to patients who have a history of Torsades de pointes unless all risk factors that contributed to Torsades have been corrected. Adavosertib has not been studied in patients with ventricular arrhythmias or recent myocardial infarction. - Corrected QT interval (QTc) >470 msec at study entry or congenital long QT syndrome. - Pregnant or lactating. - Serious active infection at the time of enrolment, or another serious underlying medical condition that would impair the patient's ability to receive study treatment. - Presence of other active cancers, or history of treatment for invasive cancer within 3 years. Patients with Stage I cancer who have received definitive local treatment within 3 years, and whom are considered unlikely to recur, are eligible. Patients with previously treated in-situ carcinoma (i.e., non-invasive) are eligible, as are patients with prior non-melanoma skin cancers. |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Research Site | Toronto | Ontario |
| Netherlands | Research Site | Amsterdam | |
| United States | Research Site | Abington | Pennsylvania |
| United States | Research Site | Augusta | Georgia |
| United States | Research Site | Boston | Massachusetts |
| United States | Research Site | Cleveland | Ohio |
| United States | Research Site | Dallas | Texas |
| United States | Research Site | Detroit | Michigan |
| United States | Research Site | Gilbert | Arizona |
| United States | Research Site | La Jolla | California |
| United States | Research Site | Los Angeles | California |
| United States | Research Site | Milwaukee | Wisconsin |
| United States | Research Site | Nashville | Tennessee |
| United States | Research Site | New York | New York |
| United States | Research Site | New York | New York |
| United States | Research Site | Oklahoma City | Oklahoma |
| United States | Research Site | San Francisco | California |
| United States | Research Site | Tampa | Florida |
| United States | Research Site | Tucson | Arizona |
| United States | Research Site | West Palm Beach | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
United States, Canada, Netherlands,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Objective Response Rate (ORR) | Objective response rate is defined as the proportion of patients achieving a complete or partial tumour response according to RECIST v1.1 criteria. | Throughout the duration of the study (up to 19 months) | |
| Secondary | Disease Control Rate (DCR) | The Disease Control Rate is defined as the proportion of patients achieving a complete response (CR), partial response (PR), or stable disease (SD) according to RECIST v1.1 criteria. | Throughout the duration of the study (up to 19 months) | |
| Secondary | Duration of Response (DoR) | Duration of Response (DoR) is defined as the time from first documented tumour response until the date of documented progression or death from any cause. | Throughout the duration of the study, approximately 19 months. | |
| Secondary | Progression Free Survival (Median, 80% CI) | Progression-free survival (PFS) was defined as the elapsed time from date of first dose of AZD1775 until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.
Progression-free survival was derived based on scan/assessment dates, not visit dates. |
Throughout the Study, Approximately 4 years | |
| Secondary | Progression Free Survival (Median, 95% CI) | Progression-free survival (PFS) was defined as the elapsed time from date of first dose of AZD1775 until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.
Progression-free survival was derived based on scan/assessment dates, not visit dates. |
Throughout the Study, Approximately 4 years | |
| Secondary | Overall Survival (Median, 80% CI) | Overall survival (OS) was defined as the elapsed time from the date of first dose of AZD1775 until death due to any cause. Any patient not known to have died at the time of the analysis was censored based on the last recorded date on which the patient was known to be alive. | Throughout the Study, Approximately 4 years | |
| Secondary | Overall Survival (Median, 95% CI) | Overall survival (OS) was defined as the elapsed time from the date of first dose of AZD1775 until death due to any cause. Any patient not known to have died at the time of the analysis was censored based on the last recorded date on which the patient was known to be alive. | Throughout the Study, Approximately 4 years | |
| Secondary | Gynecologic Cancer Intergroup (GCIG) CA-125 Response | The GCIG CA-125 response is defined as the proportion of patients achieving a 50% reduction in CA-125 levels from baseline, if baseline level is =2 x the upper limit of normal (ULN) within 2 weeks prior to starting treatment. Response must be confirmed and maintained for at least 28 days. | Throughout the study, approximately 4 years | |
| Secondary | The Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) by Maximum CTCAE Grade. | The number of patients experiencing at least one treatment-related adverse event (TEAE) by maximum CTCAE grade.
Severity Grade 1 = Mild; Severity Grade 2 = Moderate; Severity Grade 3 = Severe; Severity Grade 4 = Life Threatening; Severity Grade 5 = Fatal |
Throughout the duration of the study (up to 19 months) | |
| Secondary | The Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) Related to Adavosertib by Maximum CTCAE Grade | The number and proportion of patients experiencing at least one treatment-related adverse event (TEAE) related to adavosertib by maximum CTCAE grade
Severity Grade 1 = Mild; Severity Grade 2 = Moderate; Severity Grade 3 = Severe; Severity Grade 4 = Life Threatening; Severity Grade 5 = Fatal |
Throughout the duration of the study (up to 19 months) | |
| Secondary | The Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) Related to Chemotherapy by Maximum CTCAE Grade | The number of patients experiencing at least one treatment-related adverse event (TEAE) related to chemotherapy by maximum CTCAE grade.
Severity Grade 1 = Mild; Severity Grade 2 = Moderate; Severity Grade 3 = Severe; Severity Grade 4 = Life Threatening; Severity Grade 5 = Fatal |
Throughout the duration of the study (up to 19 months) | |
| Secondary | Serious Adverse Events | The number of patients experiencing at least one serious adverse event (SAE). | Throughout the duration of the study (up to 19 months) | |
| Secondary | Serious Adverse Events Leading to Death | The number of patients experiencing at least one serious adverse event (SAE) leading to death. | Throughout the duration of the study (up to 19 months) | |
| Secondary | Treatment-Related Adverse Events Related to Adavosertib Leading to Treatment Discontinuation | The number of patients experiencing at least one treatment-related adverse event related to adavosertib leading to treatment discontinuation. | Throughout the duration of the study (up to 19 months) | |
| Secondary | Treatment-Related Adverse Events Related to Adavosertib Leading to Dose Reduction | The number of patients experiencing at least one treatment-related adverse event related to adavosertib leading to dose reduction. | Throughout the duration of the study (up to 19 months) | |
| Secondary | Treatment-Related Adverse Events Related to Adavosertib Leading to Treatment Interruption | The number of patients experiencing at least one treatment-related adverse event related to adavosertib leading to treatment interruption. | Throughout the duration of the study (up to 19 months) | |
| Secondary | Treatment-Related Adverse Events Related to Chemotherapy Leading to Treatment Discontinuation | The number of patients experiencing at least one treatment-related adverse event related to chemotherapy leading to treatment discontinuation. | Throughout the duration of the study (up to 19 months) | |
| Secondary | Treatment-Related Adverse Events Related to Chemotherapy Leading to Dose Reduction | The number of patients experiencing at least one treatment-related adverse event related to chemotherapy leading to dose reduction. | Throughout the duration of the study (up to 19 months) | |
| Secondary | Treatment-Related Adverse Events Related to Chemotherapy Leading to Treatment Interruption | The number of patients experiencing at least one treatment-related adverse event related to chemotherapy leading to treatment interruption. | Throughout the duration of the study (up to 19 months) | |
| Secondary | Single Dose Adavosertib Cmax | Maximum plasma concentration of adavosertib after a single oral dose (Cycle 1 Day 1) in combination with IV infusion of commonly used chemotherapy agents, including gemcitabine, paclitaxel, and carboplatin. | Pre-dose, 0.5 hr, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr | |
| Secondary | Multiple Dose Adavosertib Cmax | Maximum plasma concentration of adavosertib after a multiple oral doses (Cycle 1 Day 3) in combination with IV infusion of 40 mg/m² pegylated liposomal doxorubicin. | Pre-dose, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr | |
| Secondary | Single Dose Adavosertib Tmax | The time to reach maximum plasma concentration of adavosertib after a single oral dose (Cycle 1 Day 1) in combination with IV infusion of commonly used chemotherapy agents, including gemcitabine, paclitaxel, and carboplatin. | Pre-dose, 0.5 hr, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr | |
| Secondary | Multiple Dose Adavosertib Tmax | The time to reach maximum plasma concentration of adavosertib after multiple oral doses (Cycle 1 Day 3) in combination with IV infusion of 40 mg/m² pegylated liposomal doxorubicin. | Pre-dose, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr |